CELLAXIA

cellaxia-logo

drug discovery bio-venture aiming at practical application of advanced research such as cell therapy .

#People #Financial #Website #More

CELLAXIA

Industry:
Biotechnology Clinical Trials Health Care Wellness

Founded:
2017-01-01

Address:
Tokyo, Tokyo, Japan

Country:
Japan

Website Url:
http://www.cellaxia.co.jp

Total Employee:
1+

Status:
Active

Contact:
03-3527-2448

Email Addresses:
[email protected]

Total Funding:
6.77 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default WordPress Wordpress Plugins Nginx Euro Contact Form 7 Pound Sterling


Current Employees Featured

not_available_image

Makoto Seki
Makoto Seki Founder & CEO @ CellAxia
Founder & CEO

Founder


not_available_image

Makoto Seki

Investors List

fukuoka-financial-group_image

Fukuoka Financial Group

Fukuoka Financial Group investment in Series B - CellAxia

mitsubishi-ufj-capital_image

Mitsubishi UFJ Capital

Mitsubishi UFJ Capital investment in Series B - CellAxia

m3_image

M3

M3 investment in Series B - CellAxia

mizuho-capital_image

Mizuho Capital

Mizuho Capital investment in Series B - CellAxia

okasan-capital-partners_image

Okasan Capital Partners

Okasan Capital Partners investment in Series B - CellAxia

miyako-capital_image

Miyako Capital

Miyako Capital investment in Series B - CellAxia

kyogin-lease-capital_image

Kyogin Lease & Capital

Kyogin Lease & Capital investment in Venture Round - CellAxia

mitsubishi-ufj-capital_image

Mitsubishi UFJ Capital

Mitsubishi UFJ Capital investment in Venture Round - CellAxia

Official Site Inspections

http://www.cellaxia.co.jp

  • Host name: c28.hpms1.jp
  • IP address: 183.90.183.45
  • Location: Osaka Japan
  • Latitude: 34.6848
  • Longitude: 135.5142
  • Timezone: Asia/Tokyo
  • Postal: 543-0062

Loading ...

More informations about "CellAxia"

セルアクシア株式会社 CellAxia Inc.|細胞の持つ潜在能力を科学 …

セルアクシア株式会社は、再生医療等製品の特性を活かして従前の医薬品では治せない疾患を画期的に改善する『次世代型の治療薬』の実用化を目指しています。See details»

セルアクシア株式会社 CellAxia Inc.|東京都中央区

Apr 1, 2017 セルアクシア株式会社(英語名 CellAxia Inc.) 所在地 〒103-0012 東京都中央区日本橋堀留町1-10-9 ログズ日本橋堀留ビル 6階: 電話番号: 03-3527-2448: FAX: 03-3527-2449: E-mail: [email protected]: 設立: 2017年1月: 資本 …See details»

CellAxia - Crunchbase Company Profile & Funding

Organization. CellAxia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email [email protected]; Phone …See details»

セルアクシア株式会社 | InfoBase

「E-MNC(CA-702)」というシェーグレン症候群の新規細胞治療薬のパイプラインを構築しています。また、非侵襲的に採取した患者の線維芽細胞から骨芽細胞等の体細胞を作成する技 …See details»

CellAxia Company Profile 2024: Valuation, Funding & Investors

JP-7500083-B2: Cell-containing pharmaceutical composition: Active: 19-Aug-2019: A61K35/15: To view CellAxia’s complete patent history, request access » CellAxia Investors (13) Investor …See details»

セルアクシア - STARTUP DB|スタートアップデータ …

新規細胞治療薬「E-MNC」の研究・開発を手がける創薬バイオスタートアップ。 「E-MNC」は、2021年6月に難病の自己免疫疾患の一つシェーグレン症候群を対象疾患とした治験計画書等を厚生労働省に提出し、同年7月に30日調査が完 …See details»

CellAxia, Inc. - Drug pipelines, Patents, Clinical trials - Synapse

Sep 26, 2024 www.cellaxia.co.jp. Last update 05 Sep 2024See details»

CellAxia - Products, Competitors, Financials, Employees, …

Cellaxia.co.jp. Overview & Products; Financials; People; Founded Year 2017. Stage Series C | Alive. Total Raised $11.48M. Last Raised $4.68M | 2 yrs ago. About CellAxia. CellAxia is a …See details»

CellAxia - Funding, Financials, Valuation & Investors - Crunchbase

How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Sep 11, 2020: Series B - …See details»

CellAxia Inc. - Portfolio Company Profile, Executives and Private ...

See CellAxia Inc.'s complete profile, including its private equity owner and the number of its executive contacts in our database. CellAxia Inc. is a drug discovery bio-venture aiming at …See details»

第三者割当増資による資金調達実施のお知らせ

Aug 19, 2022 【本件に関するお問合せ先】 セルアクシア株式会社 管理部 電話番号:03-3527-2448 URL https://www.cellaxia.co.jp E-mail [email protected] 細胞の持つ潜在能力を科学するSee details»

Celaxia Co., Ltd. Asset Profile - Preqin

Based in Tokyo, Japan, and founded in 2017 by CEO Makoto Seki, CellAxia Inc. operates as a biopharmaceutical company specializing in regenerative medicine. The company engages in …See details»

CellAxia - Overview, News & Competitors | ZoomInfo.com

CellAxia is a company that operates in the Biotechnology industry. It employs 21-50 people and has $5M-$10M of revenue. The company is headquartered in Tokyo, Tokyo, Japan. ... View …See details»

セルアクシア の企業情報 - バフェット・コード

企業名 住所 純利益 資産; ガイア・インベストメント: 東京都中央区日本橋横山町7番18号: 717百万円: 82,817百万円See details»

セルアクシアが7億円を調達: 創薬バイオベンチャー

Sep 16, 2020 セルアクシア株式会社(英語名 CellAxia Inc.) 所在地 〒103-0012 東京都中央区日本橋堀留町1-10-9 ログズ日本橋堀留ビル 6階: 電話番号: 03-3527-2448: FAX: 03-3527-2449: E …See details»

CellAxia Inc. - Wiki - Golden

CellAxia Inc. is a Tokyo-based company in the pharmaceutical industry. Overview Structured Data Issues Contributors Activity. Contents. Help us improve this page by adding information. Visit …See details»

CellAxia - Contacts, Employees, Board Members, Advisors & Alumni

Organization. CellAxia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. CellAxia has 1 …See details»

CellAxia - Tech Stack, Apps, Patents & Trademarks - Crunchbase

Dec 10, 2024 Organization. CellAxia . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Active Tech Count 6. Monthly …See details»

Patents Assigned to CellAxia Inc. - Justia Patents Search

Aug 19, 2019 Applicant: CellAxia Inc. Inventors: Takayuki ASAHARA, Amankeldi A. SALYBEKOV, Makoto SEKI Ask a Lawyer. Question: Add details. 120. Additional Details: …See details»

Makoto Seki - Founder & CEO @ CellAxia - Crunchbase

Primary Organization . CellAxia . ... Makoto Seki is the Founder & CEO at CellAxia. CellAxia Founder & CEO. Related Hubs. Edit Related Hubs Section. Hub Name . CB Rank (Hub) …See details»

linkstock.net © 2022. All rights reserved